ANDAs: Pre-Submission of Facility Information Related to Prioritized Generic Drug Applications (Pre-Submission Facility Correspondence) Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
November 3, 2017
May 6, 2020
b98ece19-e078-446b-9b61-835924e31cd9
Related Documents
Establishing Impurity Specifications for Antibiotics
Guidance DocumentApril 20, 2026Center for Drug Evaluation and Research
Clinical Pharmacology Considerations for Peptide Drug Products
Guidance DocumentDecember 14, 2023Center for Drug Evaluation and Research
Sameness Evaluations in an ANDA — Active Ingredients
Guidance DocumentNovember 8, 2022Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox